The Vaccine Contract Manufacturing Market Will Reach $1047.3m In 2019 Predicts New Visiongain Report

13 September 2018
Pharma

A new report by visiongain predicts that the global vaccine contract manufacturing market will reach $1047.3m in 2019. This forecast and others appear in Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies, published in December 2015. Visiongain is a business information provider based in London, UK.

Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies examines the current and future trends in the vaccine contract manufacturing market. Vaccines are a healthcare success, with widespread immunisation eradicating some of the world’s most deadly diseases. The development of new vaccines has historically been limited to a number of large companies due to the high costs involved. However, a growing number of virtual companies and the international demand for new therapeutic vaccines especially, growth in the vaccine contract manufacturing market is accelerating. Another key aspect of the market is the rise of emerging markets as not only a destination for vaccines, but as high quality manufacturing centres for them. While visiongain does not believe this will completely reshape the market, its effects cannot be discounted.

In this report, visiongain examines in detail a number of key national markets (US, Germany, UK, France, Spain, Italy, Japan, China, Russia, Brazil and India), as well as looking at the overall vaccine contract manufacturing market and the key players within it. To give scale to the contract manufacturing business, a global vaccines market forecast is also included. Using visiongain’s experience and market knowledge, as well as a wide variety of sources, forecasts have been built for both national and overall markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Visiongain’s report provides revenue forecasts to 2026 for the vaccine contract manufacturing market and its leading national markets. The report discusses selected leading companies which hold significant shares of the market. These companies include Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, IDT Biologika, Lonza, Meridian Life Science, Sigma Aldrich Fine Chemicals (Merck) and Synco Bio Partners.

Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“Global Cell Therapy Technologies market set to grow to $23bn by 2024” says new Visiongain report

Cell therapy technologies are used across various research areas including gene therapy, cancer vaccines, regenerative medicine, biologics and others. Increasing global disease burdens and the need for more personalised & precision medicine has led to massive growth in the cell technology market, which is likely to increase over the next decade.

19 February 2020

Read

“Global Asthma & COPD market set to grow to $49 bn by 2025” says new Visiongain report

The Asthma and COPD market has the potential to bring several blockbuster drugs to the marketplace due to the increasingly segmented sub-groups of patients.

17 February 2020

Read

“Global Rheumatoid Arthritis Drugs market estimated to grow at a CAGR of 0.6% in the second half of the forecast period” says Visiongain report

Another factor driving the growth in the market is the discovery of new molecules that are involved in the disease process, and hence, new strategies for treating the disease.

17 February 2020

Read

Visiongain assesses that the Contract Research Organisations (CROs) market will generate revenues of $38.0 billion in 2020

Global clinical research organizations market was valued at $34.9 billion in 2019 and is projected to grow at a CAGR of 9.5% during the forecast period 2020-2030.

12 February 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever